Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 344

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Seroconversion rates following COVID-19 vaccination among patients with cancer

Open access
Thakkar, Astha, Gonzalez-Lugo, Jesus D., Goradia, Niyati, Gali, Radhika, Shapiro, Lauren C., Pradhan, Kith, Rahman, Shafia, Kim, So Yeon, Ko, Brian, Sica, R. Alejandro, Kornblum, Noah, Bachier-Rodriguez, Lizamarie, McCort, Margaret, Goel, Sanjay, Perez-Soler, Roman, Packer, Stuart, Sparano, Joseph, Gartrell, Benjamin, Makower, Della, Goldstein, Yitz D., Wolgast, Lucia, Verma, Amit, Halmos, Balazs·2021·Cancer Cell

Abstract

As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2021.06.002

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Metadata

Authors
Thakkar, A., Gonzalez-Lugo, J. D., Goradia, N., Gali, R., Shapiro, L. C., Pradhan, K., Rahman, S., Kim, S. Y., Ko, B., Sica, R. A., Kornblum, N., Bachier-Rodriguez, L., McCort, M., Goel, S., Perez-Soler, R., Packer, S., Sparano, J., Gartrell, B., Makower, D., Goldstein, Y. D., Wolgast, L., Verma, A., & Halmos, B.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2021-08
Volume
39
Issue
8
Pages
1081-1090.e2
ISSN
1535-6108 (ISSN-L)
OpenAlex
W3172958999
Cited by
344
References
42
FWCI
23.47
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Seroconversion rates following COVID-19 vaccination among patients with cancer. https://app.cochat.ai/papers/10.1016/j.ccell.2021.06.002
The paper
Thakkar, A., Gonzalez-Lugo, J. D., Goradia, N., Gali, R., Shapiro, L. C., Pradhan, K., Rahman, S., Kim, S. Y., Ko, B., Sica, R. A., Kornblum, N., Bachier-Rodriguez, L., McCort, M., Goel, S., Perez-Soler, R., Packer, S., Sparano, J., Gartrell, B., Makower, D., . . . Halmos, B. (2021). Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. https://doi.org/10.1016/j.ccell.2021.06.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.